SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR ( DUBLIN Calif. April 04 2007 /PRNews...)

SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR

DUBLIN, Calif., April 04, 2007 /PRNewswire-FirstCall/ -- SuperGen Inc. announced today that it will have multiple presentations at the American Association for Cancer Research Annual Meeting on April 14-18 in Los Angeles. These presentations will focus on data concerning many of SuperGen's current oncology programs including its lead tyrosine kinase inhibitor compound, MP470 and its ability to block Rad51, a key protein target involved in cancer cell drug resistance. Presentations will take place in the exhibit hall of the Los Angeles Convention Center.

    The schedule of SuperGen's presentations is:


                                                              Poster

    Date     Time (PDT)           Title                       Number/Section


    Sunday,   1 p.m. - 5 p.m.     Hydrochloride salt of       #1540

    April                         MP470, a potent

    15                            suppressor of Rad51,        Poster

                                  improves                    Section 31

                                  bioavailability and

                                  tolerability


    Monday,   8 a.m. - 12 p.m.    Discovery and               #2380

    April                         characterization of a

    16                            series of Axl kinase        Poster

                                  inhibitors using the        Section 30

                                  CLIMB(TM) process


    Monday,   8 a.m. - 12 p.m.    Discovery and               #2387

    April                         characterization of

    16                            small molecule              Poster

                                  inhibitors for Jak2         Section 30


    Monday,   8 a.m. - 12 p.m.    Zebrafish as a model        #2229

    April                         mechanistic screen

    16                            for small molecule          Poster

                                  inhibitors of DNMT1         Section 23

'"/>




Page: 1 2 3 4 
Related medicine technology :

1. SuperGen to Present at the C.E. Unterberg, Towbin Emerging Growth
Opportunities Conference
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor
Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
4. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease
5. Expert Opinion Highlights Avigens AV411 as Potential New
Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development
Highlights at deCODE R&D Event
7. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its
Ghrelin Antagonist Program at the American Diabetes Associations
Annual Meeting
8. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes
Association Conference Highlighting Ability of Glufast to Maintain
Glycemic Control in Patients with Type 2 Diabetes
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations
Highlighting Mechanism of Action and Clinical Activity of
Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American
Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. Ambrilia Highlights Encouraging Data for its HIV Integrase
Inhibitor Program and Recent Developments at Annual Meeting
11. July Issue of Journal of Antimicrobial Chemotherapy Highlights
Study of Factive Tablets for Five-Day Treatment of
Community-Acquired Pneumonia

Post Your Comments:

( DUBLIN Calif. April 04 2007 /PRNews...)SuperGen to Highlight Oncology Pipeline Data in Multiple,Presentations at AACR,Health